Madrigal Pharmaceuticals’ (MDGL) “Buy” Rating Reiterated at Cowen

Share on StockTwits

Cowen reiterated their buy rating on shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) in a research report report published on Wednesday morning.

Several other equities analysts have also recently issued reports on MDGL. BidaskClub raised Madrigal Pharmaceuticals from a strong sell rating to a sell rating in a research note on Tuesday, October 30th. Citigroup began coverage on Madrigal Pharmaceuticals in a research note on Tuesday, September 4th. They set a buy rating and a $340.00 target price on the stock. Goldman Sachs Group cut Madrigal Pharmaceuticals from a buy rating to a neutral rating and set a $314.00 target price on the stock. in a research note on Monday, August 6th. Oppenheimer set a $300.00 target price on Madrigal Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, August 8th. Finally, Zacks Investment Research raised Madrigal Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, July 24th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have given a buy rating to the stock. The company has an average rating of Hold and a consensus target price of $314.00.

Shares of MDGL traded down $7.10 during mid-day trading on Wednesday, hitting $184.49. 158,758 shares of the company’s stock traded hands, compared to its average volume of 212,828. Madrigal Pharmaceuticals has a 1 year low of $38.82 and a 1 year high of $325.98.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by ($0.03). As a group, equities analysts anticipate that Madrigal Pharmaceuticals will post -2.25 EPS for the current year.

Hedge funds have recently modified their holdings of the stock. FNY Investment Advisers LLC purchased a new stake in Madrigal Pharmaceuticals in the second quarter worth $110,000. Meeder Asset Management Inc. grew its stake in Madrigal Pharmaceuticals by 296.4% in the second quarter. Meeder Asset Management Inc. now owns 436 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 326 shares during the period. SG Americas Securities LLC purchased a new stake in Madrigal Pharmaceuticals in the second quarter worth $124,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Madrigal Pharmaceuticals in the second quarter worth $140,000. Finally, Public Employees Retirement Association of Colorado purchased a new stake in Madrigal Pharmaceuticals in the third quarter worth $157,000. 53.06% of the stock is currently owned by institutional investors.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company's lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.

Recommended Story: Calculate Your Return on Investment (ROI)

Analyst Recommendations for Madrigal Pharmaceuticals (NASDAQ:MDGL)

Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Insureum Achieves Market Cap of $0.00
Insureum Achieves Market Cap of $0.00
Reviewing Geovax Labs  & Its Competitors
Reviewing Geovax Labs & Its Competitors
LPL Financial  Price Target Lowered to $66.00 at Morgan Stanley
LPL Financial Price Target Lowered to $66.00 at Morgan Stanley
Westaim  and Becton Dickinson and  Financial Contrast
Westaim and Becton Dickinson and Financial Contrast
Reviewing Heritage Global  and J2 Global
Reviewing Heritage Global and J2 Global
United Microelectronics  Stock Price Up 6.5%
United Microelectronics Stock Price Up 6.5%


Leave a Reply

© 2006-2018 Ticker Report